derived from salicylic acid, the parent of aspirin.
1 compound · filter the full catalogue by this class
SANA is a nitroalkene derivative of salicylate, the parent of aspirin, developed for obesity and type 2 diabetes. In obese mice it reduced weight, liver fat and insulin resistance by raising creatine-dependent energy expenditure in fat tissue. MVD1 is the name its first human trial ran under. That trial was a small, 15-day phase 1 study, which reported good tolerability and early effects on body weight and glucose.